Follow
Wayne Martin
Wayne Martin
Verified email at ualberta.ca
Title
Cited by
Cited by
Year
Levodopa and the progression of Parkinson's disease
Parkinson Study Group
New England Journal of Medicine 351 (24), 2498-2508, 2004
22632004
Unified Huntington's disease rating scale: reliability and consistency
K Kieburtz, JB Penney, P Como, N Ranen, A Feigin, D Abwender, ...
Movement disorders 11 (2), 136-142, 1996
19791996
Brain Blood Flow Measured with Intravenous H215O.: II. Implementation and Validation
ME Raichle, WRW Martin, P Herscovitch, MA Mintun, J Markham
Journal of Nuclear Medicine 24 (9), 790-798, 1983
13381983
Diffusion tensor imaging of white matter tract evolution over the lifespan
C Lebel, M Gee, R Camicioli, M Wieler, W Martin, C Beaulieu
Neuroimage 60 (1), 340-352, 2012
11452012
Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL‐PET study
AL Whone, RL Watts, AJ Stoessl, M Davis, S Reske, C Nahmias, AE Lang, ...
Annals of neurology 54 (1), 93-101, 2003
10352003
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group
DE Hobson, AE Lang, WRW Martin, A Razmy, J Rivest, J Fleming
Jama 287 (4), 455-463, 2002
7332002
Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography.
MA Mintun, ME Raichle, WR Martin, P Herscovitch
Journal of nuclear medicine: official publication, Society of Nuclear …, 1984
7231984
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study
Parkinson Study Group
Archives of neurology 59 (12), 1937-1943, 2002
7112002
Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology
JM Miyasaki, W Martin, O Suchowersky, WJ Weiner, AE Lang
Neurology 58 (1), 11-17, 2002
5752002
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease
Parkinson Study Group
Archives of Neurology 61 (4), 561-566, 2004
5662004
A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease
Huntington Study Group
Neurology 57 (3), 397-404, 2001
5012001
Psychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD study
K Duff, JS Paulsen, LJ Beglinger, DR Langbehn, JC Stout, ...
Biological psychiatry 62 (12), 1341-1346, 2007
4652007
Midbrain iron content in early Parkinson disease: a potential biomarker of disease status
WRW Martin, M Wieler, M Gee
Neurology 70 (16_part_2), 1411-1417, 2008
4512008
Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease
DB Calne, JW Langston, WRW Martin, AJ Stoessl, TJ Ruth, MJ Adam, ...
Nature 317 (6034), 246-248, 1985
4251985
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ...
Neurology 78 (10), 690-695, 2012
4172012
Preparing for preventive clinical trials: the Predict-HD study
JS Paulsen, M Hayden, JC Stout, DR Langbehn, E Aylward, CA Ross, ...
Archives of neurology 63 (6), 883-890, 2006
3852006
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
Ninds Net-Pd Investigators
Neurology 66 (5), 664-671, 2006
3832006
Nigrostriatal function in humans studied with positron emission tomography
WRW Martin, MR Palmer, CS Patlak, DB Calne
Annals of Neurology: Official Journal of the American Neurological …, 1989
3461989
Longitudinal change in regional brain volumes in prodromal Huntington disease
EH Aylward, PC Nopoulos, CA Ross, DR Langbehn, RK Pierson, JA Mills, ...
Journal of Neurology, Neurosurgery & Psychiatry 82 (4), 405-410, 2011
2932011
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit
MF Beal, D Oakes, I Shoulson, C Henchcliffe, WR Galpern, R Haas, ...
JAMA neurology 71 (5), 543-552, 2014
2922014
The system can't perform the operation now. Try again later.
Articles 1–20